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OBJECTIVE — To measure prospectively bone mineral density (BMD) of the Charcot and
non-Charcot foot in 36 diabetic patients presenting with acute Charcot osteoarthropathy.
RESEARCH DESIGN AND METHODS — Calcaneal BMD was measured with quanti-
tativeultrasoundatpresentation,at3monthsofcasting,andatthetimeoftheclinicalresolution.





CONCLUSIONS — Although the Charcot foot was treated with casting until clinical reso-
lution, there was a signiﬁcant fall of BMD only from presentation up until 3 months of casting.
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S
tudies on bone mineral density
(BMD) have shown a reduction of
BMD of the Charcot foot compared
with the contralateral non-Charcot foot
(1–4). However, it is not known what
happens to BMD in the natural history
of the osteoarthropathy. The aim of this
study was to measure prospectively the
longitudinal changes of BMD of the
Charcot and non-Charcot foot in pa-
tients presenting with acute Charcot
osteoarthropathy.
RESEARCH DESIGN AND




22 years [16.9–26.3]) who presented to
the Diabetic Foot Clinic between Febru-
ary 2002 and October 2008 with a red,
hot, swollen foot and a skin temperature
2°C compared with that of the con-
tralateral foot and who had no previous
ofﬂoading treatment. Foot skin tempera-
turesweremeasuredbyDermatemp1001
(Exergen, Watertown, MA). All patients
were treated with ofﬂoading and cast im-
mobilization until the temperature differ-
ence between the feet was 2°C at two
consecutive monthly visits (5,6).
BMD of the calcaneum was measured
by quantitative ultrasound (Sahara Clini-
cal Bone Sonometer; Hologic, Waltham,
MA) as described previously (1). BMD of
theCharcotfootwascomparedwithBMD
ofthenon-Charcotfootatpresentation,at
3 months, and at the time of the clinical
resolution at the end of the casting treat-
ment using a paired Student t test. One-
wayrepeated-measuresANOVAwasused
to assess the longitudinal change of BMD
and foot skin temperature difference be-
tween feet. Pairwise comparisons be-
tweenthemeansforBMDatpresentation,
at 3 months, and at clinical resolution
were carried out to assess the effect of
time. Results are presented as means
(95% CI). Differences were considered
signiﬁcant at P  0.05. All subjects gave
informed written consent to participate.
ThestudywasapprovedbyKing’sCollege
Hospital NHS Trust Research Ethics
Committee and carried out in accordance
with the Declaration of Helsinki.
RESULTS— BMD of the Charcot foot
was signiﬁcantly reduced compared with
BMD of the non-Charcot foot at presenta-
tion (0.456 g/cm
2 [95% CI 0.411–0.502]
vs. 0.494 g/cm
2 [0.456–0.533]; P 
0.001), at 3 months of casting (0.433
g/cm
2 [0.389–0.476] vs. 0.482 g/cm
2
[0.393–0.564]; P  0.001), and at the
time of clinical resolution (0.432 g/cm
2
[0.388–0.477] vs. 0.479 g/cm
2 [0.393–
0.579]; P  0.001).
Time to clinical resolution was 8.2
months (95% CI 6.9–9.5). The multivar-
iate analysis demonstrated a signiﬁcant
fall of BMD of the Charcot foot from the
time of presentation to the time of clinical
resolution(Wilks0.525,P0.001).
Thiswasnotedinbothtype1(Wilks
0.528, P  0.006) (Fig. 1A) and type 2
diabetes (Wilks 0.497, P  0.015)
(Fig. 1B).
The pairwise comparisons between
the different time points demonstrated a
signiﬁcant fall of BMD of the Charcot foot
from presentation to clinical resolution
(P  0.015). The fall of BMD from pre-
sentation (0.456 g/cm
2 [95% CI 0.411–
0.502]) to 3 months of casting (0.433
g/cm
2 [0.389–0.476]) was highly signif-
icant (P  0.001), both in type 1 (P 
0.002) and type 2 diabetes (P  0.004),
but the subsequent fall of BMD from 3
months of casting to clinical resolution
was not signiﬁcant (0.433 g/cm
2 [0.389–
0.476] to 0.432 g/cm
2 [0.388–0.477];
P  0.949). This applied to both type 1
(P  0.748) and type 2 diabetes (P 
0.832).
In contrast to the Charcot foot, the
multivariate analysis in the non-Charcot
foot indicated that there was a nonsignif-
icant fall of BMD from the time of presen-
tation (0.494 g/cm
2 [95% CI 0.456–
0.533]) to the time of resolution (0.479
g/cm
2 [0.393–0.579], Wilks 0.947;
P  0.439), and this was present in both
type 1 (Wilks 0.935, P  0.583)
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0.799, P  0.259) (Fig. 1B).
There was a signiﬁcant fall of the foot
skin temperature difference between the
Charcot and non-Charcot foot from the
time of presentation to the time of resolu-
tion (Wilks 0.423, P  0.001). The
foot skin temperature difference also fell
signiﬁcantly from 3.5°C (95% CI 3.1–
4.1) at presentation to 2.2°C (1.8–2.2) at
3 months of casting (P  0.001), and the
latter further signiﬁcantly reduced to
1.4°C(1.1–1.8)atclinicalresolution(P
0.001).
CONCLUSIONS— This study dem-
onstrated that from the time of presenta-
tion to clinical resolution there was a
signiﬁcant fall of BMD of the Charcot foot
butnotofthenon-Charcotfoot.Although
there was a signiﬁcant fall of BMD of the
Charcot foot at 3 months of casting com-
pared with BMD at presentation, there
was no further signiﬁcant reduction of
BMD from 3 months of casting up until
clinical resolution, despite the ongoing
casting of the Charcot foot.
Our study showed a fall of BMD at 3
monthsofcastingintheCharcotfootboth
in type 1 and type 2 diabetes. The foot
skin temperature of the Charcot foot was
still2°Cgreatercomparedwiththatofthe
non-Charcotfoot,andthismayhavebeen
related to inﬂammatory osteolysis that
would have resulted in a fall of BMD (4).
Increased levels of proinﬂammatory cyto-
kines have been reported in patients with
acute Charcot osteoarthropathy, and this
may explain this observed reduction of
BMD (7–9).
However, this fall of BMD may have
been aggravated by the cast immobiliza-
tion of the Charcot foot, and a recent case
report has documented a fall of BMD in a
total contact cast, highlighting the effect
of immobilization (10). In our study, al-
though there was a signiﬁcant fall of BMD
of the Charcot foot from presentation to 3
months of casting, this was not followed
by a further signiﬁcant fall of BMD up
until clinical resolution despite the ongo-
ingcasting.Thus,itismorelikelythatthe
overall fall of BMD was related to inﬂam-
matory osteolysis rather than casting
immobilization.
Alimitationofthisstudyisthatwemea-
sured BMD of the calcaneum not BMD at
the site of Charcot osteoarthropathy. Nev-
ertheless, the calcaneum is a disease-
responsive bone with a high metabolic
turnoverrate(11)andshouldhavereﬂected
overall changes of BMD in the foot.
In conclusion, although the Charcot
foot was treated with casting until clinical
resolution, there was a signiﬁcant fall of
BMD only from presentation until 3
months of casting. This may be related to
the inﬂammatory osteolysis of Charcot
osteoarthropathy.
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